Share Name Share Symbol Market Type Share ISIN Share Description
Salvarx Group Plc LSE:SALV London Ordinary Share IM00BZ4SS228 ORD 2.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 4.50 0.00 0.00 0.00 0.00 - 0.00 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -0.5 1.0 4.5 2

Salvarx Share Discussion Threads

Showing 151 to 173 of 500 messages
Chat Pages: Latest  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
22/3/2018
16:41
well they could, but i'm rather disillusioned with riskier and small cap investing I think you;re better off going to a casino
kristini2
22/3/2018
11:22
The problem is that those who subscribed at 33p, not the highest quality of investor, have lost heart and there could be some tax loss selling, not to mention the fact that the shares have fallen on very low volume. I think Kristin's time horizon is far too pessimistic and the shares could easily double in the blink of an eye.
wiseacre
20/3/2018
18:38
It's fairly illiquid with little volumes period, and so one must be prepared to hold long term, i mean maybe 5 years + I am thinking maybe 10 years It will not take too much given the market cap here to see positive price action, and so the risk reward over 5 years looks good. The speculative nature is a given
kristini2
20/3/2018
16:25
Good point. What I don't understand is why the price peaked at 45p and is now 20p (ish). surely there are not sufficient fickle holders to cause the price to fall and fall. Most must be in it for the long haul. So why the volatility ?
dexdringle
20/3/2018
16:20
Come on dexdringle you should know that biotech has long lead times but with cancer immunotherapy lead times are quicker. If you have no patience you shouldn't be here.
wiseacre
19/3/2018
15:01
....if they could be so kind as to see their way, if it isn't too much trouble, to start MAKING SOME IMPRESSIVE PROFITS then I suspect that we all might become a little more 'enchanted'.......
dexdringle
19/3/2018
10:46
The American management is disenchanted with AIM and, I believe, could be looking at a listing their side of the Atlantic
wiseacre
15/3/2018
23:41
Yep I don't think I'd invest just on Mellon The American angle more interesting
the stigologist
15/3/2018
17:42
You are quite right Stig but this one is led by an American who came out of Bristol Myers Squibb, the leaders in immunotherapy, and has done zilch PR for the company. The company was floated at 33p two years ago and has come a long way since then. Time will tell.
wiseacre
15/3/2018
16:43
Kumo bull break-out today.
blueball
15/3/2018
10:20
maybe it's a good shout on Mellon but I don't think he's regarded as being that good that people would just buy his tips just because he's tipped something he is a bit hit and miss and often times on public listed stuff miss
the stigologist
14/3/2018
16:47
He may mention it or it will appear as part of a portfolio of options on a slide presentation. I hold.
fig1
13/3/2018
10:34
Kumo Bull break-out yesterday.
blueball
12/3/2018
14:42
edit. March 9 2018....180p - Northland reiterated their 180p tp, first mentioned 23-10-2017 although there's been some strong news since that 10/2017 mention. Only 36.47m shares in total here at SALV, so still only a tiny market cap - barely over £10m, even after today's uplift of now abt 29p at the best ask. Cheap. f
fillipe
12/3/2018
10:50
Jim Mellon retweeted this hTtps://twitter.com/greenhamneggs/status/971720358100389888
the stigologist
12/3/2018
10:29
+ 49%....! f
fillipe
12/3/2018
10:22
does look that way
the stigologist
12/3/2018
10:08
This company is hugely undervalued.
wiseacre
08/3/2018
12:36
Ian Walters, CEO of SalvaRx, said: "I am delighted with the portfolio of assets that we have put together as well as the teams behind these technologies. We have seen substantial progress across the portfolio and now are beginning to evolve into a clinical stage company with multiple assets expected in the clinic by the end of the year. The appetite for early stage immuno-oncology assets is still strong with recent record-breaking deals showing significant premiums (in February Bristol Myers Squibb acquired 35% of Nektar's compound NKTR-214 for $1.8billion upfront with additional milestones). Analysts also predict that recent tax reform in the US will stimulate additional mergers and acquisitions in this area. SalvaRx is well poised to deliver a series of novel first in class products which can augment the pipelines in big pharma."
the stigologist
27/2/2018
15:53
hTtps://www.investegate.co.uk/fastforward-inn-ltd--ffwd-/rns/investee-company-update--intensity-therapeutics/201802271543521310G/
the stigologist
23/10/2017
07:09
Hmm no wonder Jim Mellon getting himself some 'cheap' warrants then!
the stigologist
10/10/2017
14:26
I am told the investment in Iox is worth £100 million Could be one to tuck away. Floated at 33p and looks cheap.
wiseacre
01/10/2017
16:57
Syncona(SYNC) on the up.Very similar business model to SALV.Regards,Fig.
fig1
Chat Pages: Latest  8  7  6  5  4  3  2  1
Your Recent History
LSE
SALV
Salvarx
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200121 10:45:39